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Abstract
Background: Return-to-work (RTW)-interventions support cancer survivors in resuming work, but come at
additional healthcare costs. The objective of this study was to assess the budget impact of a RTW-intervention,
consisting of counselling sessions with an occupational physician and an exercise-programme. The secondary
objective was to explore how the costs of RTW-interventions and its financial revenues are allocated among the
involved stakeholders in several EU-countries.
Methods: The budget impact (BI) of a RTW-intervention versus usual care was analysed yearly for 2015–2020 from
a Dutch societal- and from the perspective of a large cancer centre. The allocation of the expected costs and
financial benefits for each of the stakeholders involved was compared between the Netherlands, Belgium, England,
France, Germany, Italy, and Sweden.
Results: The average intervention costs in this case were €1,519/patient. The BI for the Netherlands was €-14.7 m
in 2015, rising to €-71.1 m in 2020, thus the intervention is cost-saving as the productivity benefits outweigh the
intervention costs. For cancer centres the BI amounts to €293 k in 2015, increasing to €1.1 m in 2020. Across
European countries, we observed differences regarding the extent to which stakeholders either invest or receive a
share of the benefits from offering a RTW-intervention.
Conclusion: The RTW-intervention is cost-saving from a societal perspective. Yet, the total intervention costs are
considerable and, in many European countries, mainly covered by care providers that are not sufficiently reimbursed.
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Background
Many cancer survivors experience difficulties in returning
to work. Approximately 40 % have not resumed work
24 months post treatment [1]. Furthermore, cancer survi-
vors have an increased risk for unemployment compared
to the general population [2, 3]. Supporting patients in
returning to the workplace may improve health and
quality of life, and avoid high societal costs associated with
unemployment and long-term inability to work [4–6].
When successful, RTW-interventions can increase prod-
uctivity through reducing sick leave and might save costs
to society. However, RTW is not or only partly reimbursed
by health insurers in most European countries, including
the Netherlands. The main reason is that the interventions
are expected to be expensive and unaffordable. However,
when they are effective, return-to-work interventions can
produce financial benefits, although their size is unknown.
To date, no budget impact analysis of these interventions
or of any other cancer rehabilitation intervention has been
published. Evidence on the budget impact would quantify
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to what extent return-to-work interventions are beneficial
from a financial point of view or if these interventions
would add costs to the system. Therefore, the primary aim
of this study was to evaluate the expected budget impact
(BI) of RTW-interventions for cancer survivors. In a budget
impact analysis, the expected financial impact of an inter-
vention on the budget of a health system is analysed [7].
Return-to-work interventions typically consist of counsel-
ling by an occupational physician directed on return-to-
work possibilities. We considered an intervention that
combines counselling with physical exercise, as a Cochrane
review showed that multidisciplinary RTW-interventions
are most effective. Moreover, physical exercise is strongly
recommended for cancer patients in several organisations’
guidelines [8–12]. The analysis was conducted from the
Dutch societal perspective and from the perspective of a
hypothetical cancer centre over the time period 2015–
2020. The latter perspective serves to estimate the BI for
cancer centres that plan to introduce RTW and want to in-
vestigate its year-by-year financial impact. The secondary
objective was to identify the allocation of costs and finan-
cial returns of providing RTW for cancer survivors for sev-
eral European countries. This provides insights in financial
incentives for and against RTW-implementation.
Methods
Budget impact analysis
The budget impact of a multidisciplinary RTW-intervention
was assessed following the International Society for
Pharmacoeconomics and Outcome Research-guidelines
over a time horizon of 5 years. We compared the situation
in which the intervention gradually is implemented to
current practice, where only 5 % of the eligible patients can
follow the intervention. We considered a Dutch societal
perspective and that of a cancer centre serving a
population of 1 m inhabitants, which equals the catch-
ment area of large European cancer centres [7, 13]. All
input parameters are presented in Table 1.
Approval of an ethics committee and the participants’
consent were not required for this research, as the data
were derived from the literature and from health profes-
sionals. Dutch law does not require medical or ethical
reviews for interviews with health care professionals.
Confidentiality was ensured by not disclosing the names
or hospitals of the interviewees and only referring to
them by country. The study on which the cost calcula-
tion is based had received approval from the respective
ethics committee [12].
Intervention description and uptake of the intervention
The RTW-intervention, including counselling and exer-
cise, is prescribed at the start of cancer treatment to all
cancer patients who potentially can and wish to resume
work. The counselling includes two one-hour sessions
with an occupational physician specialised in oncology.
The exercise component consists of 24 group sessions of
moderate to high-intensity physiotherapy in groups of five.
The duration of the exercise programme is 12 weeks,
starting at the onset of chemotherapy. Some hospitals also
provide a sports medical capacity-assessment before and
after the programme. A more detailed description of the
intervention was published previously [12, 14].
Eligible population
Patients with any type of cancer are eligible when they are;
a) of working age, i.e. between 25 and 64 years, b) treated
with curative intent [4, 15, 16], c) expected to have a treat-
ment outcome that allows returning to work, d) wishing
to return to work, and e) willing to follow the intervention.
For each criterion, the percentage of all cancer patients to
whom this applies was analysed and is given in Table 1.
The percentage of patients who are eligible was calculated
by multiplying 100 % with the percentages of all criteria.
This resulted in an eligibility percentage of 12 % of all
cancer patients that are diagnosed yearly (see Table 1).
Capacity
As there currently is insufficient capacity for providing
the intervention, not all patients eligible for a multidis-
ciplinary return-to-work intervention can follow it. Rea-
sons for the limited capacity are that the implementation
in general is still in the starting phase and that many
health professionals are not fully aware of the possibilities
that cancer rehabilitation offers. In order to offer the inter-
vention to all eligible patients and provide the intervention
on a larger scale, hospitals would, e.g., first need to employ
more physical therapists and occupational physicians,
and create the appropriate organisational structures
for providing the intervention on a larger scale.
As a result of the above, currently only a small (i.e.
5 %) subgroup of survivors is prioritized to receive
multidisciplinary rehabilitation treatment. Thus, of the
12 % of the cancer patients who are eligible, 5 % can fol-
low the intervention. This capacity is assumed to remain
at that 5 % level throughout the analysis’ time horizon
for current practice. This is compared to the situation in
which hospitals start to implement the intervention and
gradually increase the capacity to enrol patients, starting
with 30 % of eligible patients in 2015–70 % in 2020.
Thus, in 2015, 30 % of the 12 % of eligible survivors fol-
low the intervention. Finally it is expected that in 2017
most of the eligible survivors (70 %) can participate in
multidisciplinary return-to-work interventions.
The capacity in a single cancer centre that is used for
the analysis from the perspective of a hypothetical can-
cer centre rises much faster, from 30 % in 2015–90 % in
2020. It is assumed that once a cancer centre decides to
offer the intervention it would take measures to relatively
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quickly provide it to all eligible patients. However, they
would also be faced by shortages of staff, especially occu-
pational physicians. The percentage from the Dutch
societal perspective remains lower, at 70 %, because it is
assumed that not every hospital will offer the inter-
vention. Thus, some hospitals will not offer return-to-work
interventions at all, whereas some offer it to 90 % of the
eligible patients, leading to an overall percentage of 70 %.
Costs of the intervention and impact on other costs
Intervention costs include staff costs, administration,
materials, and 42 % overhead, according to the Dutch
Table 1 Input parameters for the budget impact analysis
Parameter Value for the
Netherlands
Value for a reference
cancer centre
Source
Cancer incidence in the Netherlands:
2015 110,215 6,533 Signaleringscommissie Kanker of the Dutch
Cancer Society, 2011 [4]
2016 112,776 6,675
2017 115,337 6,816
2018 117,899 6,805
2019 120,460 7,097
2020 123,021 6,237
Percentage of eligible patients:
% with 5-year survival 62 % Dutch Cancer Registry [15]
% aged 25–64 40 % Dutch Cancer Registry [14]
% with treatment outcome that allows 80 % Assumption
RTW
% who want to resume work 85 % Assumption
% who wish to follow intervention 70 % Assumption
% eligible for intervention 12 % (=1*0.32*0.80*0.85*0.70) Product of the above
Capacity in current practice:
2015 5 % 5 % Assumptions
2015 5 % 5 %
2016 5 % 5 %
2017 5 % 5 %
2018 5 % 5 %
2019 5 % 5 %
2020 5 % 5 %
Capacity in new situation:
2015 20 % 30 % Assumptions
2016 30 % 60 %
2017 40 % 90 %
2018 50 % 90 %
2019 60 % 90 %
2020 70 % 90 %
Percentage of patients for whom the
intervention is reimbursed in current situation:
100 %
Percentage of patients for whom the
intervention is reimbursed in new situation:
10 % Assumption
Intervention costs € 1,517 Assessment of the costs based on intervention
description [13] and information provided
from the staff who delivered the intervention.
Additional weekly working hours in the
new situation
5.8 h Thijs et al., 2011 [17]
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manual for cost research [17]. Volumes of resource use
were obtained from the intervention protocol and health
professionals participating in a feasibility study of the
intervention [12, 14]. Unit costs were determined follow-
ing Dutch guidelines for pharma-economic research
[17]. Staff training costs of €335 were considered as part
of the overhead. Hospitals receive reimbursement for
providing RTW-interventions to patients formally indi-
cated for multidisciplinary rehabilitation. This is circa
10 % of the eligible population. In current practice, all
patients who receive the RTW-interventions are indi-
cated for multidisciplinary rehabilitation and thus re-
ceive reimbursement.
An impact on other costs occurs through changes in
the patients’ productivity. The effect of RTW on resuming
work was taken from a Dutch trial. In the intervention
group the participants followed an 18-weeks exercise
programme, consisting of a high intensity resistance and
endurance training. This was compared to standard
medical care that was received by an age-matched control
group. Patients with any type of cancer of 18–65 years of
age were included who were treated with curative intend
and were in paid employment at the time of diagnosis.
110 patients were included in the analysis, 72 in the inter-
vention group and 38 in the control group. The adherence
of the participants was very high with 96 % and thus
slightly higher than for the multidisciplinary return-to-
work intervention where it was 86 %. A significant differ-
ence in the time to resume work was not found. However,
the intervention was found to increase productivity signifi-
cantly by 5 · 8 h/week for one year [18]. Thus, the partici-
pants in the intervention group were able to work more in
the long-term. This 5.8 h/week that are worked more than
in current practice was used for the productivity benefit in
this analysis and was €30.02/h, according to the Dutch
manual for cost research [17].
Analysis
For analysing the budget impact, a spreadsheet model
(Fig. 1) was created in Microsoft Excel (Redmond, WA).
The budget impact equals the total cost of the RTW-
intervention minus the productivity gains that accrue
from RTW, in the new situation vs. current practice [7].
In the model, the number of patients following the inter-
vention was identified by multiplying cancer incidence
with the percentage of eligible patients and the capacity
of hospitals to provide the intervention. The number of
patients was then multiplied with the intervention
costs, which resulted in the total costs of the RTW-
intervention. For the Dutch societal perspective, the
productivity gains equal the number of patients who
follow the intervention multiplied with the additional
yearly working time generated and with the hourly
productivity costs. For the cancer centre’s perspective,
the benefit consists of receiving reimbursed from the health
insurer for delivering RTW to the 10 % of the patients
indicated for multidisciplinary rehabilitation Fig. 2.
Sensitivity analysis
The influence on the budget impact of the effectiveness
of the intervention was analysed, in order to test the ro-
bustness of the model outcomes. For this purpose, the
effect in a range of 0 to 5.8 additional weekly working
hours, which corresponds to 0–302 h a year, was used to
display its effect on the budget impact graphically. This
also allowed analyzing where the budget impact changes
from being cost-saving to adding costs, i.e. where the
line of the budget impact crosses the x-axis from being
cost-saving to adding costs.
Analysis of the incentive structure to implement RTW in
the Netherlands and in several EU-countries
The allocation of costs and financial returns across stake-
holders involved in RTW was analysed, to identify poten-
tial (dis)incentives for implementing RTW-interventions.
For this purpose, an email survey was conducted among
comprehensive cancer centres that are members of the
Organisation of European Cancer Institutes (n = 40) from
the Netherlands, Belgium, England, France, Germany,
Italy, and Sweden. At least one respondent from each
country was required. In the survey each cancer centre-
representative with professional knowledge about the
healthcare and welfare system in their respective country,
was asked to tick in a list of stakeholders which of these
(1) bear the costs of sick leave of cancer patients, (2) are
responsible for the reintegration of cancer patients
into the workplace, (3) bear the costs for offering an
RTW-intervention, and (4) benefit financially from can-
cer patients following a RTW intervention. The list of
stakeholders included health insurers, hospitals, patients,
employers, pension insurance schemes, and the state. The
nature of the financial benefits depends on the stakeholder
and includes, e.g., for hospital reimbursement by the pa-
tients’ health insurers, for health insurers a reduction in
the patients’ future health care needs, for patients the
ability to continue working and receive an income, or
for employers the prevention of sick leave and subse-
quent production losses.
For the analysis, the results of the survey were
assessed in 2*2 tables showing how many and which
stakeholders both pay and gain from RTW, how many
only pay or only gain, and how many do not pay or gain.
Results
Budget impact analysis
Base case results
The number of patients following the intervention under
current (Dutch) practice on national level was estimated
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to be 651 in 2015 and increase to 726 patients in 2020.
This increase only reflects the rising cancer incidence,
while the percentage of patients who are eligible for the
interventions remains stable in this model. In the new
situation in which RTW-interventions are rolled out
more widely, 2,602 patients would participate in the
intervention in 2015. As cancer incidence and the
capacity both rose, it is estimated that in 2020,
10,166 patients would follow the intervention.
The same reasoning as described above was applied to
estimate the number of patients receiving RTW in a
large cancer centre. In current practice this number
would rise from 39–43 in the 5-year period in our
model, due to the growth in cancer incidence. After
implementing RTW, the number could increase from
231 in 2015–769 in 2020, as the capacity for treating the
eligible patients is assumed to grow.
The average costs of the RTW-intervention are esti-
mated at €1,517 per patient, of which €567 (37 %) are
for consultations with the occupational physician, €879
(59 %) for the exercise part, and €46 for administration
and printed materials.
The total health care costs when implementing
RTW for the Netherlands are €4.0 m to €15.4 m
from 2015–2020. The benefits in terms of productiv-
ity gains are €23.6 m to €92.0 m in 2015–2020. The
BI for the Netherlands is €-14.7 m in 2015, rising to
€-71.1 m in 2020, meaning that from a societal per-
spective RTW for cancer survivors in the Netherlands
would be cost-saving. The productivity gains are large
and outweigh the intervention costs by far. In fact,
with rising incidence and a growing proportion of
patients following RTW, cost savings further increase
year-by-year. However, the intervention is rather
expensive to its providers and the initial health care
costs are considerable.
For a large cancer centre, the costs for the interven-
tion compared to current practice, from 2015–2020
increase from €351 k to €1.2 m. The financial benefit in
terms of reimbursement from 2015–2020 is only €58.6 k
to €116.8 k. The BI for a cancer centre is €292.8 k in
2015 and rises to €1.1 m in 2020. Thus, for a cancer
centre providing this service, the high intervention costs
cause RTW to be an expensive intervention to offer, as
Fig. 1 Structure of the budget impact model
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they get only reimbursed for 10 % of the patient popula-
tion. Table 2 and Fig. 2 show the base case results.
Sensitivity analysis
Figure 3 shows that even when the benefit of the RTW-
intervention was much smaller than expected based on
current data the intervention would still be cost-saving.
The health care costs equal the productivity benefits, i.e.
the BI is zero, when the RTW-intervention enables pa-
tients to return to work 50.6 h earlier in 2020 compared
to usual care. This value corresponds to an increased
weekly working time of approximately 1 h/week, which
is more than five times lower than the value used in the
base case analysis (5.8 h/week).
Analysis of the incentive structure for implementing RTW
The Netherlands
Health care providers that offer RTW-interventions
carry their costs themselves, apart from the health insur-
ances’ reimbursement for about 10 % of patients with a
multidisciplinary rehabilitation need. The financial returns
from earlier RTW are received by employers, the patients,
and pension funds. Thus, a misalignment exists between
the stakeholders that pay for RTW and those that receive
the financial benefits in terms of increased productivity or
in preventing invalidity pension. As this situation discour-
ages to offer RTW on a large scale, its substantial cost-
savings to society are forgone. A cancer centre or hospital
would need to highly value the intangible benefits, such as
being a provider of high-quality care, attractiveness for pa-
tients, or being a leading cancer centre, in order to make
up for the costs. See Table 3 for the results of this analysis.
EU-countries
Eleven of the 40 questionnaires (28 %) that were sent
to cancer centres were returned (Belgium= 1, England = 2,
France = 1, Germany = 2, Italy = 3, Sweden = 1, The
Netherlands = 1). Respondents included researchers, sci-
entific directors, medical directors, a director of the psy-
chosocial service, an HR-manager, and a social worker. In
Fig. 2 Results of the base case analysis. A negative budget impact indicates that the intervention is cost-saving. The positive budget impact for
the cancer centre results from the situation that in the Netherlands, the costs for RTW are not reimbursed for most patients. Thus, if a hospital is
offering the intervention they need to finance it themselves
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Table 2 Results of the budget impact analysis
2015 2016 2017 2018 2019 2020
DUTCH SOCIETAL PERSPECTIVE
Current practice:
Number of patients 651 666 681 696 711 726
Health care costs 987.901 € 1.010.858 € 1.033.815 € 1.056.772 € 1.079.729 € 1.102.686 €
Productivity benefits 5.889.947 € 6.026.819 € 6.163.690 € 6.300.562 € 6.437.434 € 6.574.306 €
New situation:
Number of patients 2.602 3.994 5.446 6.959 8.532 10.166
Health care costs 3.951.605 € 6.065.149 € 8.270.522 € 10.567.724 € 12.956.753 € 15.437.611 €
Productivity benefit 23.559.787 € 36.160.912 € 49.309.524 € 63.005.623 € 77.249.210 € 92.040.284 €
Budget impact −14.706.137 € −25.079.802 € −35.909.126 € −47.194.109 € −58.934.752 € −71.131.054 €
PERSPECTIVE OF A HYPOTHETICAL CANCER CENTRE
Current practice:
Number of patients 39 39 40 40 42 43
Health care costs 58.560 € 59.828 € 61.093 € 60.999 € 63.611 € 64.864 €
Benefits (reimbursement) 58.560 € 59.828 € 61.093 € 60.999 € 63.611 € 64.864 €
New situation:
Number of patients 231 473 724 723 754 769
Health care costs 351.358 € 717.939 € 1.099.674 € 1.097.987 € 1.144.994 € 1.167.550 €
Benefit (reimbursement) 58.560 €a 71.794 € 109.967 € 109.799 € 114.499 € 116.755 €
Budget impact 292.798 € 646.145 € 989.706 € 988.188 € 1.030.495 € 1.050.795 €
aAccording to the model, this would be €35,136, assuming that hospitals receive reimbursement for 10 % of the patients. As this is lower than the benefit in the
current situation, it is expected that as long as in the new situation there still are patients with a multidisciplinary rehabilitation need (for whom the costs are
reimbursed by insurance), these would be treated preferentially to patients for whom the costs are not reimbursed
Fig. 3 The impact of earlier RTW on the budget impact in 2020. From 2020 on a steady state is assumed
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four of the six other EU-countries included in this ana-
lysis, similar misalignments of costs and financial benefits
as in the Netherlands were observed, as shown in Fig. 4.
The most beneficial situation for implementation of
RTW-interventions is found in Germany and France. In
Germany, the employers, health insurance, and pension
insurance have financial incentives to support RTW, by
being both responsible for financing RTW and receiving
its financial benefits. In France this applies to employers
and health insurers. In Belgium, the National Health
Service in England, and the Netherlands patients/
employees and one other stakeholder pay for and gain
from RTW, while in Italy and Sweden the patients are the
only stakeholders mentioned in both categories.
Discussion
From the Dutch societal perspective, the BI of the RTW-
intervention for cancer survivors is negative, i.e. the
RTW-intervention yields more financial benefits than it
costs. The BI for cancer centres is high, as these mainly
shoulder the costs of providing the intervention. The
way in which costs and financial benefits in the
Netherlands are allocated, leads to a disincentive to offer
RTW-interventions for cancer survivors. Of the six
countries included in the European comparison, only
Germany and France provide a payment structure that
rewards the provision of RTW by health care providers.
In order to reduce the misalignment of costs and fi-
nancial benefits in and outside the healthcare system
and facilitate larger scale patient access, the payment
and reimbursement structures need adjustment. For
many countries, a more sustainable way of financing
RTW may include shifting a larger share of the costs to
employers or pension schemes, which primarily benefit
financially from RTW-interventions. Alternatively within
the current financing system, the intervention could be
prescribed more selectively to patients at highest risk of
not returning to work [18–20]. In addition, the counsel-
ling by the occupational physician could possibly be pre-
scribed as a mono-dimensional intervention, when this
matches with the individual patient’s need. As the costs
for the counselling make up 37 % of the intervention
costs, this would decrease the health care costs consider-
ably for all stakeholders involved.
This study has some limitations; first, the potential
overall health benefits of exercise programs, beyond
returning to work, that may lead to lower future health
care resource use are not included in the analysis [19].
Thus, the cost savings of RTW-interventions are prob-
ably underestimated. Welfare benefits that are influ-
enced by RTW, such as sick pay, and invalidity and
retirement pension, have not been included due to a lack
of data. This might also lead to an underestimation of
the potential cost savings and precludes a quantification
of the financial benefits of RTW to the state. Finally,
while a healthcare system perspective is recommended
for BI analysis [7], we deviated from this recommenda-
tion to show the relation between the intervention costs
and the productivity gains that extend beyond the health
care system.
Regarding transferability of the costs of the Netherlands
to other countries, it can be noted that the intervention
costs mainly consist of labor costs and thus depend on the
income level in the respective country. The number of pa-
tients who follow the intervention is a product of cancer
incidence, the percentage of eligible patients, and capacity
Table 3 Distribution of RTW intervention costs and financial returns across the stakeholders for the Netherlands
Health insurance Hospitals/Health
care providers
Employers Patients/Employees The state Pension insurance
scheme
Responsibilities
in RTW
General responsibility
for reimbursing
necessary health care
Sick pay for first
2 years, reintegration
of sick employees
into the workplace
Sick pay after
2 years of
inability to work
Carrying the
costs of RTW
interventions
Reimbursement
for patients with
multidisciplinary
rehabilitation need
Intervention
costs
Receiving the
financial returns
of RTW
Lower future health
care costs, however,
high budget impact
Fewer productivity
losses, no replacement
for employee needed
Ability to generate
an income
Less early-retirement-
pension payments
- – - + – -
Incentive for
financing RTW for
cancer patientsa
Lower future health
care costs are long-run,
considerable budget
impact
Carrying the costs,
but not receiving
financial returns.
Status quo is financially
beneficial for employers.
Incentive for an
acceptable out-of-
pocket payment
Not receiving
any financial
returns
Status quo is financially
beneficial.
aThe distribution of costs and financial benefits in which the costs as well as the financial returns are incurred by the same stakeholder, incentivizes the financing
and implementation of RTW. For stakeholders who receive financial benefits, but do not need to carry the costs, the current financing arrangement is very attractive.
Thus, they do not have an interest in changing the financial structure. However, if they would need to take over (a part of) the financing, this would be acceptable.
For stakeholders who need to carry the costs, but do not receive financial returns, an incentive to finance RTW does not exist, as they it will only cost them
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for treating patients. These would need to be adjusted to
the respective country as well.
Moreover, the limitations of the data that was used for
the productivity benefits which were derived from the
study by Thijs et al. [18] need to be mentioned. First,
given the evidence for the effectiveness of exercise it was
considered unethical to randomize patients. Thus, in-
stead, an age-matched control group recruited in an-
other hospital was used. Still, the baseline characteristics
of both groups were comparable. Second, most of the
participants, around 70 %, were breast cancer patients
and around 80 % were female. This is an issue in cancer
survivorship research in general [20] but yields questions
about the generalizability of the outcome. As breast can-
cer patients often are relatively young and have good
treatment outcomes, they participate in intervention
research more often than other groups. However, the
criteria for being eligible for the intervention included
treatment with curative intent and a treatment outcome
that is sufficient for being able to return to work. Thus,
this also is a selected group of cancer survivors, of which
many might be breast cancer survivors, as these patients
would fulfil these criteria more often than e.g. lung can-
cer patients. Therefore, and given the robustness of our
findings against alternative effectiveness inputs (i.e. 5
times smaller), we consider it safe to conclude that the
intervention is cost-saving for the general group of
cancer survivors who are eligible for multidisciplinary
return-to-work interventions.
In order to increase patient access to RTW-
interventions, a consensus among stakeholders on
how to arrange the financing of RTW-interventions
needs to be found when the value of RTW-interventions
is sufficiently demonstrated. For this purpose, more
research is needed that assesses the effectiveness of
RTW, and on the subgroups of patients who would
benefit the most. Moreover, the value of the intan-
gible benefits for the stakeholders and the interven-
tion’s indirect benefits would need to be investigated
to support this process.
Fig. 4 Incentive in EU-countries for financing RTW for cancer patients. The stakeholders placed in the framed square have a financial incentive for
financing RTW interventions. The more stakeholders are placed in the framed square, the greater the incentives for implementing RTW are. If this is the
patient/the employee, this is less beneficial then when this is another stakeholder, as it is not feasible that the patients carries the costs for the intervention
alone. HI = Health insurance, HO =Hospital or health care provider, E = Employer, S = State, PI = Pension insurance scheme, P = Patient/employee
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Conclusions
This study analysed the BI of a multidisciplinary RTW-
intervention for cancer survivors and explored the allo-
cation of the costs and financial benefits of RTW across
the stakeholders involved in six EU-countries. From the
Dutch societal perspective, the productivity gains of the
RTW-intervention outweigh the intervention costs by
far. However, the total healthcare costs are considerable
and shouldered almost exclusively by health care pro-
viders. Therefore, the BI of RTW for cancer centres is
very high and the current financing system does not pro-
vide the appropriate incentives for implementing RTW
on a larger scale. A similar misalignment of financial in-
centives exists in other EU-countries, with only Germany
and France providing an incentive for stakeholders to pay
for RTW. To ensure patient access to RTW-programs,
future investigations into the real-world effectiveness and
societal impact of RTW-programs for cancer survivors are
needed, as well as a consensus on how to fix the current
financial misalignment.
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